Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 23Carcinoma, Hepatocellular 20Nasopharyngeal Carcinoma 12Triple Negative Breast Neoplasms 11Esophageal Neoplasms 11Stomach Neoplasms 10Esophageal Squamous Cell Carcinoma 10Sarcoma 7Squamous Cell Carcinoma of Head and Neck 6Lung Neoplasms 6Uterine Cervical Neoplasms 5Melanoma 5Hodgkin Disease 5Recurrence 4Colorectal Neoplasms 4Breast Neoplasms 4Small Cell Lung Carcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3Neoplasm Metastasis 3NSCLC 3Advanced Gastric Cancer 3Respiratory Tract Diseases 2Rectal Neoplasms 2Osteosarcoma 2Neoplasms 2Nasopharyngeal Neoplasms 2Metastatic Gastric Adenocarcinoma 2Lymphoma, Extranodal NK-T-Cell 2Lung Diseases 2

Interventions

Rituximab 57Cyclophosphamide 40Vincristine 26Prednisone 25Doxorubicin 22Cytarabine 18Lenalidomide 17Etoposide 17Gemcitabine 12Melphalan 8Filgrastim 8Cisplatin 8zanubrutinib 7Peripheral Blood Stem Cell Transplantation 7Oxaliplatin 7N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 7Methotrexate 7Ifosfamide 7Carmustine 7R-CHOP protocol 6fludarabine phosphate 5Vindesine 5Radiotherapy 5Dexamethasone 5Decitabine 5Busulfan 5ibrutinib 4Methylprednisolone 4Epirubicin 4Cyclosporine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, Large B-Cell, Diffuse × camrelizumab × Clear all
NCT04476459 2021-03-15

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

Sun Yat-sen University

Phase 1/2 Unknown
33 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡